17 apr: Aktietilbagekøbsprogram i SP Group A/S
23 apr: Indre værdi af SmallCap Danmark A/S er opgjort til 20,5 kr. pr. a..
17-04-2019 16:52:56

Genmab Announces Data to be Presented at 2019 ASCO Annual Meeting

Media Release

Copenhagen, Denmark, April 17, 2019

14 industry sponsored abstracts regarding Genmab programs selected for presentation at ASCO Annual Meeting

Genmab A/S (Nasdaq Copenhagen: GEN) announced today that 14 industry sponsored abstracts regarding Genmab programs were accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from May 31 to June 4, 2019. The titles of the abstracts are currently available on the ASCO iPlanner website, with the full abstracts scheduled to be published on May 15, 2019. A list of accepted industry sponsored abstracts is provided below, and includes ten daratumumab abstracts, two of which were accepted for oral presentations, one abstract on enapotamab vedotin, and two abstracts on tisotumab vedotin (Trial in Progress abstracts).

“We are pleased that once again a wide selection of abstracts concerning Genmab proprietary and partnered programs was selected for presentation at the prestigious ASCO Annual Meeting. We are especially looking forward to the first full presentations of data from the COLUMBA and CASSIOPEIA daratumumab Phase III trials,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “We are equally excited to begin sharing with the oncology community early data from enapotamab vedotin and ongoing trials in progress for tisotumab vedotin.”

Representatives from Genmab will be in attendance at ASCO, booth #24159.

List of Industry Sponsored Abstracts:

Daratumumab (Submitted by Janssen Biotech, Inc.):

Phase 3 Randomized Study of Daratumumab + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Vs VTd in Transplant-eligible Newly Diagnosed Multiple Myeloma: CASSIOPEIA Part 1 Results – Oral presentation, Sunday, June 2, 10:45 AM – 10:57 PM CDT

Efficacy and Safety of the Randomized, Open-Label, Non-inferiority, Phase 3 Study of Subcutaneous Versus Intravenous Daratumumab Administration in Patients with Relapsed or Refractory Multiple Myeloma: COLUMBA – Oral presentation, Sunday, June 2, 11:09 AM – 11:21 AM CDT

Efficacy of Daratumumab + Bortezomib/Thalidomide/Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma Based on Minimal Residual Disease Status: Analysis of the CASSIOPEIA Trial –Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Stem Cell Yield and Transplantation Results from Transplant-eligible Newly Diagnosed Multiple Myeloma Patients Receiving Daratumumab + Bortezomib/Thalidomide/Dexamethasone (D-VTd) in the Phase 3 CASSIOPEIA Study –Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma: MAIA – Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Faster and sustained improvement in health-related quality of life for newly diagnosed multiple myeloma patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) vs Rd alone: MAIA – Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma based on cytogenetic risk: updated subgroup analysis of CASTOR – Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma: updated subgroup analysis of POLLUX based on cytogenetic risk – Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab in patients with transplant-eligible newly diagnosed multiple myeloma: a multicenter, randomized, phase 3 study (PERSEUS) – Poster, Monday, June 3, 8:00 AM – 11:00 AM CDT

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab in patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy: a multicenter, randomized, phase 3 study (CEPHEUS) – Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Tisotumab vedotin (Submitted by Seattle Genetics):

SGNTV-001: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or

Metastatic Disease in Solid Tumors – Poster presentation, Saturday, June 1, 2019, 8:00 AM – 11:00 AM CDT

Phase 2 Trial of Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer (innovaTV 208) – Poster presentation, Saturday, June 1, 2019, 1:15 PM – 4:15 PM CDT

Enapotamab vedotin:

First-in-human, dose-escalation, phase 1 trial to evaluate safety of anti-Axl antibody–drug conjugate enapotamab vedotin in solid tumors – Poster presentation, Saturday, June 1, 2019, 8:00 AM – 11:00 AM CDT

Ofatumumab (Submitted by Novartis):

Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab and chlorambucil: Final analysis of the phase 3 COMPLEMENT 1 trial –Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.


Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Media Release no. 06

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V




Relateret indhold
16 sep - 
Mandagens aktier: Svingende Lundbeck endte lavere i rød..
16 sep - 
Aktier/middag: Lundbeck vender rundt og topper rødt C25..
16 sep - 
Aktier/åbning: Lundbeck helt i bund på milliardopkøb i ..
Relateret debat
19 sep - 
Det var på det gamle Nordnet, men nu kører det fint ige..
19 sep - 
Gl. Nordnet kører fint. BB
19 sep - 
Tror du kigger hos Nordnet? Genmab er handlet mange gan..

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 sep
GENMAB/GUGGENHEIM: LØFTER KURSMÅLET MED 12,4 PCT. 06:36 Finanshuset Guggenheim Securities løfter sit..
13 sep
13.9.19: “Novartis' ofatumumab to be 'strong' competitor to Roche drug, says Deutsche Bank Deutsche ..
13 sep
BofA/Merrill analyst Sachin Jain upgraded Genmab to Buy from Neutral with an increased price target ..
13 sep
Vi kunne jo starte med 1000 hver, men det flytter nok ikke det store. Tror på Genmab er et guldæg, e..
13 sep
Mit svar var et forsøg på at besvare QueenMary og IKKE nogen anbefaling. Har desværre heller ikke se..
13 sep
13 sep
Kan du så ikke bare købe 20.000 stk. så sker der nok lidt med kursen.   Taastrup 
13 sep
Når man skimmer de resultater, der deles på Twitter, lader det til at der er tale om et meget succes..
13 sep
Company Announcement Details from the ASCLEPIOS I & II studies of subcutaneous ofatumumab (OMB157) ..
13 sep
Hvad skete der lige kl.14:14...der stiger aktien lige 26 point, for derefter at smide 40 igen.   Er ..

OECD sænker global vækstprognose for de kommende år

19-09-2019 11:20:24
Organisationen for Økonomisk Samarbejde og Udvikling (OECD) sænker sin globale vækstprognose for de kommende år, idet organisationen nu ser yderligere risici i verdensøkonomien.OECD venter nu en global vækst i bruttonationalproduktet (BNP) på 2,9 pct. i år og 3,0 pct. næste år.Det er en nedrevidering fra henholdsvis 3,2 pct. og 3,4 pct. i den seneste prognose.For USA er vækstprognosen sænket til 2..

Aktier/tendens: Udsigt til rød start ovenpå FED-møde

19-09-2019 08:25:07
Der er umiddelbart udsigt til små fald fra starten af den danske aktiehandel torsdag, hvor øjne og ører kan rette sig mod Ørsted, Simcorp og Sydbank. Dermed følger markedet onsdagens tendens efter tilbagegang efter rentemødet i den amerikanske centralbank, Federal Reserve (Fed).Japanske aktier ligger højere, futures på amerikanske aktier ligger op til 0,4 pct. lavere, mens DAX-futuren ligger 0,1 p..

Lars Christensens Verden - Episode 26: Sidste uges quant quake varsler nye tider på de finansielle markeder

Relaterede nyheder
18-09-2019 19:17:00
Begivenheden er af nogle blevet omtalt som et jordskælv i de globale markeder, og nej det var ikke ECB's seneste rentebeslutning eller den renteforhøjelse eller -nedsættelse, Fed annoncerer onsdag aften, dansk tid. Det er heller ikke oliepriserne, der har bevæget sig voldsomt ovenpå weekendens angreb på de saudiske olieinstallationer og Trumps Iran-tweets i kølvandet herpå, men derimod det såkaldt..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
Aktier/tendens: Novo Nordisk får markedet til at holde vejret
Novo misser primært endemål i sammenligningsstudie med fransk rival
Novo står foran stor eksamen - kan åbne dør til 200 milliarder - GENT
Ørsted vælger kæmpe GE-mølle: "Overraskende det sker så hurtigt"
Vestas/JPMorgan: Skærer 40 kr. af kursmålet til 445 kr.

Relaterede aktiekurser

Genmab A/S 1.380,50 -0,1% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
20. september 2019 09:39:53
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190829.2 - EUROWEB6 - 2019-09-20 09:39:53 - 2019-09-20 09:39:53 - 1 - Website: OKAY